What support do you have for the use of Lovenox in the treatment of DVT?
Clinical studies of Lovenox support its safety and efficacy in the treatment of DVT with or without PE. In a multi-center, parallel group study, 900 patients with acute DVT were randomized to either inpatient treatment with Lovenox administered 1.5 mg/kg once a day SC, Lovenox administered 1.0 mg/kg every 12 hours SC, or heparin IV bolus (5,000 IU) followed by a continuous infusion. All patients in the study received treatment with warfarin sodium within 72 hours of the initiation of Lovenox or heparin therapy. The results of this study revealed that both Lovenox injections were equivalent to standard heparin therapy in the prevention of recurrent venous thromboembolism. A clinical study by Levine and colleagues evaluated 501 patients with acute DVT. These patients were randomized to either outpatient treatment with Lovenox or inpatient treatment with heparin. It is important to mention that patients who were not eligible for outpatient treatment were excluded from the study and only t
